Circulating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women

• Main Authors: Min Joo Seon, So Yoon Hwang, Yujeong Son, Juhyun Song, Oh Yoen Kim
• Format: Article
• Language: English
• Published: MDPI AG 2021-03-01
• Series: Nutrients
• Subjects: glucagon-like peptide-1; metabolic syndrome; early indicator; women
• Online Access: https://www.mdpi.com/2072-6643/13/3/865

Glucagon-like peptide-1 (GLP-1), an incretin hormone, plays an important role in regulating glucose homeostasis. In this study, the applicability of circulating GLP-1 levels as an early indicator of metabolic syndrome (MetS) risk was examined. Women without diagnosed diseases were grouped according to their number of MetS risk factors (MetS RFs) (no RFs as Super-healthy, <i>n</i> = 61; one or two RFs as MetS risk carriers, <i>n</i> = 60; 3 ≤ RFs as MetS, <i>n</i> = 19). The circulating GLP-1 levels and homeostasis model assessment insulin resistance (HOMA-IR) scores were significantly higher in the MetS group than in the other two groups. The GLP-1 levels correlated positively with adiposity, HOMA-IR, blood pressure, and high sensitivity C-reactive protein (hs-CRP), but not with fasting glucose and lipid profiles, whose significances were maintained after adjustments for age, smoking and drinking habits, menopausal status, and total calorie intake. The GLP-1 levels also increased proportionally with the number of MetS RFs. In the MetS group, the GLP-1 levels were much higher in individuals with obesity (body mass index ≥ 25 kg/m²). In conclusion, the circulating GLP-1 level may be applicable as a potential early indicator of MetS risk in women without diagnosed diseases. Further study with a large population is needed to confirm the conclusion.